Verrica Pharma shows potential abscopal effect of VP-315 for basal cell carcinoma treatment in Phase 2 data.

Verrica Pharmaceuticals announced Phase 2 clinical data showing their drug VP-315 may trigger an abscopal effect, reducing untreated basal cell carcinoma (BCC) tumors beyond the injection site. This suggests VP-315 could activate the immune system broadly, potentially treating multiple BCC lesions and residual disease after surgery. The data showed an average 86% tumor size reduction and complete clearance in some untreated tumors, indicating a promising non-surgical option for BCC patients. Verrica will present these findings at the 2026 Society for Investigative Dermatology Annual Meeting, aiming to further validate VP-315's unique benefits.